Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Blackhawk Growth Corp BLRZF


Primary Symbol: C.BLR Alternate Symbol(s):  C.BLR.WT

Blackhawk Growth Corp. is a Canada-based investment holding company. The Company invests in equity and debt instruments of companies to generate positive returns for shareholders. It focuses on investing in multiple companies across a variety of sectors across North America. The Company has focused its investments on the health, cannabis and cannabidiol (CBD) industries, in both Canada and the United States.


CSE:BLR - Post by User

Post by bveilleuon Feb 08, 2021 8:12am
148 Views
Post# 32498598

BLR Submits Requested Additional info to Health Canada

BLR Submits Requested Additional info to Health Canada

Vancouver, British Columbia – TheNewswire - February 8 , 2021 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:0JJ); (CNSX:BLR.CN); (OTC:BLRZF) (the “Company”), has submitted the required additional information for its ExProbe SARS-CoV-2 Testing Kit Health Canada Interim Order (“IO”) Submission. The Corporation received correspondence from Health Canada on Friday, January 8th requesting additional information to be provided for its ExProbe SARS-CoV-2 Testing Kit. Health Canada provided a timeline of 10 days to submit the information with the option of (up to) a 30-day extension that the corporation acted on. Blackhawk is pleased to say all 227 pages of requested documentation have been compiled and submitted to Health Canada on the agreed upon date of February 6th  2021.  

Blackhawk is also pleased to announce that it has received correspondence from Health Canada on Friday, January 29th regarding its SARS-CoV-2 IgG/IgM Rapid Test Kit application which is now “under review”. The corporation has taken the position that Health Canada is now actively reviewing the IO. The Health Canada Interim Order (“IO”) for its SARS-CoV-2 IgG / IgM Rapid Test Kit application was submitted on November 4th, 2020 requesting additional information to be provided for its ExProbe SARS-CoV-2 Testing Kit. Blackhawk is working with the manufacturer and its compliance team to ensure the requested information is provided in short-order. Health Canada has provided a timeline of 10 days to submit the information with the option of a 30-day extension if required.

 

Blackhawk will continue to update its shareholders as the application process with Health Canada proceeds.

 

Blackhawk makes no representations or provides any guarantees on Health Canada’s review timelines.

About Blackhawk Growth

Blackhawk Growth is an investment issuer looking to create substantial value for our shareholders through the acquisition and development of high growth opportunities. The company has focused its investments in the health, cannabis and CBD industries in both Canada and the United States. Its portfolio of companies include Sac Pharma, Trip Pharma, Noble Hemp, Spaced Food and NuWave Foods.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

<< Previous
Bullboard Posts
Next >>